Medtronic plc Medtronic plc

Medtronic plc

MDT

Clasificación en acciones #184
Medtronic plc is a leading global medical technology enterprise that invents,... Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
Precio por acción
$94.59
Capitalización bursátil
$120.99B
Cambio (1 día)
1.76%
Cambio (1 año)
-1.39%
País
IE
Comercio Medtronic plc (MDT)

Categoría

Healthcare
Ratio P/E de Medtronic plc (MDT)
Ratio P/E al May 2026 TTM: 21.39
Según los últimos informes financieros y el precio de las acciones de Medtronic plc, el P/E actual (TTM) de la empresa es 21.39. Al final de 2024, la empresa tenía un P/E de 28.98.
Historial del ratio P/E de Medtronic plc desde 2000 hasta 2026
Relación P/E al final de cada año
Año Ratio P/E Cambiar
2026 (TTM) 21.39 -8.48%
2025 23.37 -19.35%
2024 28.98 -9.95%
2023 32.18 15.76%
2022 27.80 -43.06%
2021 48.83 75.64%
2020 27.80 9.46%
2019 25.40 -28.52%
2018 35.53 24.91%
2017 28.44 -9.80%
2016 31.53 -0.78%
2015 31.78 65.27%
2014 19.23 40.13%
2013 13.72 23.30%
2012 11.13 -23.39%
2011 14.53 -6.85%
2010 15.60 -5.77%
2009 16.55 -32.91%
2008 24.67 13.60%
2007 21.72 -8.07%
2006 23.62 -33.21%
2005 35.37 13.16%
2004 31.26 -13.97%
2003 36.33 -33.97%
2002 55.03 7.28%
2001 51.29 -9.73%
2000 56.83 0.00%
Relación P/E para empresas similares o competidores
Empresa P/E Ratio Diferencia del P/E Ratio País
33.11 54.80%
US
28.94 35.33%
US
17.34 -18.93%
US
- -
DE
49.68 132.30%
US
¿Cómo leer un P/E ratio?

El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.

Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.

Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.